Effect of promoter variants in the ADIPOQ gene on the response to rosiglitazone in patients with type 2 diabetes mellitus

XU Jing,ZHANG Rong,HU Cheng,WANG Congrong,QIN Wen,YU Weihui,XIANG Kunsan,JIA Weiping

2012-01-01

Abstract:Objective To evaluate the effect of two common promoter variants (rs266729 and rs16861194) in the ADIPOQ gene, which encodes adiponectin, on the response to rosiglitazone monotherapy for type 2 diabetes mellitus (T2DM). Methods Totally 103 newly diagnosed T2DM patients took orally rosiglitazone for 48 weeks. Clinical parameters associated with glycolipid metabolism were measured before and after treatment. Genotyping at rs266729 and rs16861194 was performed for all the patients. Results The minor allele frequency (MAF) for rs266729 was 22.0% (40/182). There were 56, 30 and 5 carriers of CC, CG and GG genotypes, respectively. The MAF for rs16861194 was 15.2% (28/184). There were 66, 24 and 2 carriers of AA, AG and GG genotypes, respectively. After rosiglitazone monotherapy, the AG+GG genotype carriers for rs16861194 had significantly higher fasting serum insulin (FIns) and homeostasis model assessment for insulin resistance (HOMA-IR) as compared with AA genotype carriers (P=0.006 9 and 0.010 4). Multivariate regression analysis revealed that rs16861194 (standard partial regression coefficient=2.01, P=0.007 5), HOMA-IR at baseline (standard partial regression coefficient=0.37, P=0.000 2) and body mass index (standard partial regression coefficient=0.19, P=0.015 5) were independent predictors for HOMA-IR after 48-week treatment with rosiglitazone. Conclusion rs16861494 at the promoter of ADIPOQ is associated with the improvement of insulin resistance after 48-week treatment with rosiglitazone in T2DM patients.